Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.53 |
| ▸ | WNT3A | P56704 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820006 | 0.90 | KMT2A (0.68) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL9419411 | 0.87 | KMT2A (0.69) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL8402203 | 0.85 | KMT2A (0.67) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL2743310 | 0.84 | KMT2A (0.78) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL10792888 | 0.84 | KMT2A (0.60) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL20382492 | 0.83 | KMT2A (0.55) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| P-Xylene SCHEMBL746836 | 0.83 | ALDH1A1 (0.52) | KMT2ARAB9AGSK3BL3MBTL1ALDH1A1 | |
| SCHEMBL16552778 | 0.83 | KMT2A (0.83) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL10881407 | 0.82 | KMT2A (0.58) | KMT2ANPC1RAB9AGSK3BCTNNB1 | |
| SCHEMBL31063989 | 0.82 | KMT2A (0.56) | KMT2ANPC1RAB9AGSK3BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853618-B1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2011-08-17 | — | — | EP | claimed |
| US-20180072721-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-9815831-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-3078373-A1 | 2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR | Genzyme Corporation (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150057309-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC | RHIZEN PHARMACEUTICALS AG (CH) | 2015-02-26 | — | — | US | disclosed |
| EP-0853618-B1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-0089769-B1 | 9-SUBSTITUTED CARBACYCLIN ANALOGUES | THE UPJOHN COMPANY (US) | 1986-10-01 | — | — | EP | disclosed |
| EP-0092352-B1 | 9-SUBSTITUTED CARBACYCLINS | THE UPJOHN COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| EP-0086611-B1 | 9-SUBSTITUTED CARBACYCLIN ANALOGUES | THE UPJOHN COMPANY (US) | 1986-05-21 | — | — | EP | disclosed |
| EP-0087237-B1 | CARBACYCLIN ANALOGUES | THE UPJOHN COMPANY (US) | 1986-05-14 | — | — | EP | disclosed |
| US-4160095-A | PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072721-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | KMT2A 1859/4885NPC1 2634/4885RAB9A 2233/4885 |
| US-20150057309-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC | MET, HGFAC, PRKCH | KMT2A 2706/4885NPC1 2080/4885RAB9A 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.